Project description
Single-cell metabolomics technology for prevention of adverse drug reactions
A major source of failure in drug development is an adverse drug reaction caused by off-target effects of drug candidates, often revealed late in the development process. Metabolomics represents a promising emerging approach to monitoring off-target effects on metabolic enzymes, providing a mechanistic understanding of drug toxicity. The challenges in metabolomics applications include the inability to resolve the drug metabolic response at single-cell level. The ERC-funded METADRUG project aims to commercialise the previously developed single-cell metabolomics. The goal is to use single-cell technology together with the data-driven metabolic modulation approach for the evaluation of single-cell metabolic response to drugs and drug candidates.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Funding Scheme
HORIZON-AG-LS - HORIZON Lump Sum GrantCoordinator
69117 Heidelberg
Germany
See on map